The new CN Bio PhysioMimix CORE combines single-organ, multi-organ, and higher-throughput configurations within one scalable platform. Fully compatible with existing PhysioMimix accessories, validated protocols, consumables, and organ model kits for seamless workflow integration.
CN Bio, a leading provider of benchtop Organ-on-a-chip (OOC) solutions that accelerate drug discovery and development, today announced the launch of PhysioMimix® Core. Combining the capabilities of CN Bio’s existing suite of instruments, PhysioMimix Core is the first OOC solution to deliver validated performance across single-organ, multi-organ, and higher-throughput configurations within one microphysiological system (MPS).
The PhysioMimix brand builds on over a decade of OOC expertise, enabling valuable insights into how drugs will perform in patients, significantly reducing risks in the clinic and minimising reliance on animal models. The technology is recognised by the U.S. FDA and harnessed by leading pharmaceutical companies, globally, supported by a range of validated protocols, consumables, and kits.
The PhysioMimix Core provides a universal end-to-end solution for recreating complex human physiology in vitro. Optimised for simplicity and functionality, it offers researchers an all-in-one platform to easily adopt, adapt, and scale OOC workflows as experiments evolve – supporting high throughput screens of up to 288 samples simultaneously. The System’s benchtop design retains unique tubeless, microfluidic engineering to reduce contamination risk and the need for daily maintenance. Recirculating media and adjustable inter/intra-organ flow rates help maintain biomarker levels, and enable long-term studies, like repeat dosing or chronic disease modelling. Configured to maximise data output and translatability, the System yields ample material recovery for multi-omics analysis.